MAPK pathway activating alteration and immunotherapy efficacy in squamous cell lung carcinoma: results from the randomized, prospective SQUINT trial.
Cappuzzo F, Ricciuti B, Delmonte A, Bonanno L, Wang X, Lye WK, Görtz A, Andrikou K, Dal Maso A, Minuti G, Papi M, Alessi JV, Di Federico A, Rodig S, Awad MM, Metro G, Attili I, Vitiello F, Pilotto S, Gori S, Rossi G, Buglioni S, Giannarelli D, Landi L.
Cappuzzo F, et al. Among authors: wang x.
Clin Cancer Res. 2025 Jan 21. doi: 10.1158/1078-0432.CCR-24-2077. Online ahead of print.
Clin Cancer Res. 2025.
PMID: 39836372